Want to join the conversation?
$BAX expects 2016 sales growth of 2-3% excluding impact of FX, and after adjusting for impact of both FX and increased U.S. competition for cyclophosphamide, $BAX sees full-year sales growth of 3-4%. On reported basis, including FX impact, $BAX sees sales to decline about 1% and EPS from continuing operations, before special items, of $1.46-1.54.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.